雷帕鸣哪里能买到

Biocon, produced in India, is a non-nephrotoxic immunosuppressant that is mainly used clinically for patients aged 13 or above who have received kidney transplants to prevent organ rejection and has significant therapeutic effects.

In recent years, rapamin has been marketed in 14 countries including Japan and the United States as a first-line drug for liver and kidney transplantation. Clinical experiments have shown that rapamin has good efficacy in heart, lung, intestinal, bone marrow and other transplants. At the same time, FK506 also plays an active role in the treatment of autoimmune diseases such as atopic dermatitis (AD), systemic lupus erythematosus (SLE), and autoimmune eye diseases.

While rapamycin is immunosuppressive, it has received clinical attention because of its non-nephrotoxicity, anti-tumor and ability to reduce cytomegalovirus infection. On the premise that the quality of the donor kidney is satisfactory, the immune risk is small, the primary kidney disease is not closely related to massive proteinuria, and patients who are not prone to delayed wound healing after surgery can consider using sirolimus in the early stage after kidney transplantation; when sirolimus is used in the early stage after kidney transplantation, appropriate antibody induction protocols should be used, and the drug concentration should be closely monitored. When switching from calcineurin inhibitor drugs to rapamycin after kidney transplantation, the age of the donor, the time since the kidney transplant surgery, the patient's renal function at the time of switching, pathological tissue damage score and urinary protein level are all important factors that affect the switching effect.

Rapamin was approved by the FDA on May 30, 2007 for the treatment of advanced renal disease. It has entered clinical phase 4 for the treatment of mantle cell lymphoma. Rapamycin is an inhibitor of the rapamycin target protein mTOR. mTOR is a downstream protein of the PI3K/AKT pathway. This pathway is abnormally activated in a variety of tumor cells. It can control the growth of tumor cells by inhibiting the activity of mTOR and thereby inhibiting the activity of its downstream S6 ribosomal protein kinase (S6K1). In addition, rapamycin also has its own activity and can be converted into rapamycin in the body to inhibit mTOR.

At present, Rapamin is on the market in China, and patients can buy it in pharmacies of major hospitals. However, as everyone knows, the original drug is relatively expensive on the market. The price of Rapamide produced in India is relatively cheaper, and patients can choose to purchase drugs from regular domestic overseas medical service companies, such as Medical Companion Travel. Our Medical Companion Travel will help you buy products at affordable prices and with ideal results. We can also send them directly to your home, so patients can buy with confidence.

Recommended related hot articles: /newsDetail/87037.html